Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1

被引：10
|
作者：
Kristensen, L. E. [1 ]
Soliman, A. M. [2 ]
Papp, K. [3 ]
Merola, J. F. [4 ,5 ]
Barcomb, L. [2 ]
Wang, Z. [2 ]
Eldred, A. [2 ]
Behrens, F. [6 ,7 ,8 ]
机构：
[1] Copenhagen Univ Hosp, Parker Inst, Bispebjerg & Frederiksberg, Copenhagen, Denmark
[2] AbbVie Inc, N Chicago, IL USA
[3] Prob Med Res & K Papp Clin Res, Waterloo, ON, Canada
[4] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol, Dept Med, Boston, MA 02115 USA
[5] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA
[6] Goethe Univ, Rheumatol, Frankfurt, Germany
[7] Goethe Univ, Fraunhofer Inst Translat Med & Pharmacol ITMP, Frankfurt, Germany
[8] Goethe Univ, Fraunhofer Cluster Excellence Immune Mediated Dis, Frankfurt, Germany
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2022年 / 36卷 / 05期
关键词：
D O I：
10.1111/jdv.17931
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E389 / E392
页数：4
相关论文
共 50 条
  • [1] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
    Erik, Lars
    Papp, Kim
    White, Douglas
    Asnal, Cecilia
    Lu, Wenjing
    Soliman, Ahmed
    Padilla, Byron
    Chen, Michael
    Ostor, Andrew
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4255 - 4258
  • [2] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    McCasland, Leslie
    White, Douglas
    Lu, Wenjing
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Behrens, Frank
    [J]. RHEUMATOLOGY, 2023, 62 (06) : 2113 - 2121
  • [3] EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PSA): 52-WEEK RESULTS FROM KEEPSAKE 1
    Kristensen, L. E.
    Keiserman, M.
    Papp, K.
    Mccasland, L.
    White, D.
    Lu, W.
    Soliman, A. M.
    Eldred, A.
    Barcomb, L.
    Behrens, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 823 - 824
  • [4] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY, 2023, 62 (06) : 2122 - 2129
  • [5] Impact of Risankizumab on Nail Psoriasis and Enthesitis Among Psoriatic Arthritis Patients with High Nail Symptom Burden
    Merola, Joseph F.
    Elewski, Boni
    Rich, Phoebe
    Amin, Ahmid
    Savage, Laura
    Papp, Kim
    Warren, Richard B.
    Shah, Megha
    Soliman, Ahmed M.
    Shi, Linyu
    Coates, Laura C.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB54 - AB54
  • [6] EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PSA): 52-WEEK RESULTS FROM KEEPSAKE 2
    Ostor, A.
    Van den Bosch, F.
    Papp, K.
    Asnal, C.
    Blanco, R.
    Aelion, J.
    Lu, W.
    Wang, Z.
    Soliman, A. M.
    Eldred, A.
    Padilla, B.
    Kivitz, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 832 - 832
  • [7] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    Mccasland, Leslie
    White, Douglas
    Carter, Kyle
    Lippe, Ralph
    Photowala, Huzefa
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael
    Padilla, Byron
    Behrens, Frank
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 617 - 632
  • [8] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Carter, Kyle
    Stakias, Vassilis
    Lippe, Ralph
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael M.
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 633 - 648
  • [9] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Carter, Kyle
    Stakias, Vassilis
    Lippe, Ralph
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael M.
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 633 - 648
  • [10] Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial
    Erik, Lars
    Keiserman, Mauro
    Papp, Kim A.
    McCasland, Leslie
    White, Douglas
    Stakias, Vassilis
    Iyile, Thomas
    Carter, Kyle
    Soliman, Ahmed
    Drogaris, Leonidas
    Chen, Michael
    Padilla, Byron
    Behrens, Frank
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2826 - 2829
12345